Tivozanib Communications Come Back To Haunt Aveo, Former Execs

Company pays $4m to settle SEC claims that it failed to publicly disclose FDA's May 2012 recommendation for a new trial of its tyrosine kinase inhibitor, the subject of a negative advisory committee review a year later. Fraud claims against three former officers continue.